Margarida Maia, PhD, science writer —

Margarida is a biochemist (University of Porto, Portugal) with a PhD in biomedical sciences (VIB and KULeuven, Belgium). Her main interest is science communication. She is also passionate about design and the dialogue between art and science.

Articles by Margarida Maia

FDA Grants Argenx Priority Review for Under-the-skin Efgartigimod

The U.S. Food and Drug Administration (FDA) has granted priority review to Argenx’s under-the-skin (subcutaneous) formulation of efgartigimod — the active ingredient in Vyvgart, the company’s approved treatment for generalized myasthenia gravis (gMG). If the subcutaneous formulation wins regulatory approval following that review, it would broaden the…

Cancer Immunotherapy Imfinzi Tied to Myasthenic Crisis

The cancer immunotherapy Imfinzi (durvalumab) may, in rare cases, trigger myasthenic crises — a serious complication of myasthenia gravis (MG) that can lead to respiratory failure. A recent case report described how an 82-year-old woman on MG remission experienced a myasthenic crisis following treatment with Imfinzi for advanced-stage lung cancer.